Welcome to our dedicated page for DuPont de Nemours SEC filings (Ticker: DD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DuPont de Nemours, Inc. filings document the regulatory disclosures of a Delaware specialty materials company with common stock listed on the New York Stock Exchange under DD. Its 8-K reports cover operating and financial results, Regulation FD disclosures, material events, board composition changes, corporate-governance matters and capital-structure disclosures.
DuPont proxy materials describe annual stockholder voting matters, director elections, governance practices, executive compensation and proposals affecting the company’s certificate of incorporation and common stock. Recent filings also document separation-related matters, including disclosures connected with the completed Qnity Electronics spin-off, as well as agreements and percentage calculations tied to the post-separation corporate structure.
DuPont de Nemours, Inc. director Donald G. Macpherson reported an acquisition of 4,030 shares of Common Stock. The shares were recorded at a price of $0.00 per share, reflecting a grant or award rather than an open-market purchase, and include shares acquired through dividend reinvestment. Following this award, his directly held position increased to 5,196.6698 shares of DuPont common stock, indicating a routine, compensation-related update to his equity holdings rather than a discretionary market trade.
BREEN EDWARD D reported acquisition or exercise transactions in this Form 4 filing.
DuPont de Nemours, Inc. director Edward D. Breen received an equity grant of 4,030 shares of Common Stock on May 21, 2026. The shares were awarded at a stated price of $0.0000 per share, reflecting a compensation-related grant rather than a market purchase.
Following this award, Breen directly holds 278,007.876 shares of DuPont common stock. This filing records a routine stock award to a board member, not an open-market transaction.
DuPont de Nemours director Kurt B. McMaken received 4,030 shares of Common Stock on May 21, 2026 as a grant or award, with shares also acquired through dividend reinvestment. The transaction carried a reported price of $0.00 per share.
Following this acquisition, McMaken directly owns about 8,257.8919 shares of DuPont de Nemours Common Stock. This is a compensation- and dividend-related share increase rather than an open‑market purchase or sale.
DuPont de Nemours, Inc. director Frederick M. Lowery reported an acquisition of company stock as a form of compensation and dividend reinvestment. He received a grant or award of 4,030 shares of Common Stock at a stated price of $0.00 per share, indicating a non-cash award rather than an open-market purchase.
After this transaction, Lowery directly held a total of 39,405.1929 shares of DuPont common stock. A footnote explains that the reported amount includes shares acquired through dividend reinvestment, showing that a portion of the increase reflects automatic reinvestment of dividends rather than discretionary market buying.
DuPont de Nemours, Inc. director James A. Lico reported an acquisition of company stock as compensation. On May 21, 2026, he received 4,030 shares of common stock in a grant/award acquisition, including shares obtained through dividend reinvestment. Following this award, he directly holds 10,839.1156 shares of DuPont common stock.
DuPont de Nemours, Inc. director Eleuthere I. du Pont reported an acquisition of company common stock. On May 21, 2026, he received 4,030 shares of common stock in a grant or other award at a stated price of $0.00 per share. A footnote explains that this amount includes shares acquired through dividend reinvestment. Following this transaction, his directly held stake increased to 42,371.4961 shares of DuPont common stock.
DuPont de Nemours, Inc. director Alexander M. Cutler reported receiving 4,030 shares of Common Stock on May 21, 2026. The shares were recorded as a grant or award at a reported price of $0.00 per share and include shares acquired through dividend reinvestment.
After this acquisition, Cutler’s directly held stake increased to 80,761.773 shares of DuPont common stock, reflecting a routine, compensation-related and dividend-linked increase in his equity position rather than an open-market purchase or sale.
DuPont de Nemours, Inc. director Ruby R. Chandy reported an acquisition of company Common Stock through a compensation-related grant. She received 4,030 shares at no stated price, including shares from dividend reinvestment, increasing her direct holdings to 25,444.3791 shares after the transaction.
DuPont de Nemours, Inc. director Amy G. Brady reported receiving a grant or award of 4,030 shares of Common Stock on May 21, 2026. The shares were acquired at no stated price per share, and the total direct holdings after this acquisition are 23,780.6788 shares. A footnote states that the total includes shares acquired through dividend reinvestment.
DuPont de Nemours, Inc. reported results from its 2026 annual meeting and detailed a reverse stock split. Stockholders elected 10 directors, approved executive compensation, ratified PricewaterhouseCoopers LLP as auditor for 2026, and authorized a reverse stock split and corresponding reduction in authorized shares.
The Board has set a 1-for-3 reverse stock split, expected to become effective at 12:01 a.m. Eastern Time on June 24, 2026, after which DuPont shares will trade on a split-adjusted basis on the NYSE under the existing ticker DD. Authorized common shares will be reduced from 1,666,666,667 to 555,555,556, and outstanding shares would have been reduced proportionately from approximately 405,058,202 to 135,019,401 if applied as of May 22, 2026, with cash paid in lieu of fractional shares.
DuPont also reaffirmed its second quarter and full-year 2026 financial guidance and provided split-adjusted adjusted earnings per share targets. For 2Q 2026, adjusted EPS guidance is approximately $1.75 (previously ~$0.59), and for full-year 2026, adjusted EPS guidance is $7.02–$7.16 (previously $2.35–$2.40), based on a projected weighted average diluted share count of about 137 million shares.